Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "antibody-therapeutic"

9 News Found

Pfizer’s sickle cell disease candidate fails Phase III trial
News | August 19, 2025

Pfizer’s sickle cell disease candidate fails Phase III trial

Inclacumab was generally well tolerated in THRIVE-131


Ichnos Glenmark Innovation receives USFDA fast track designation for ISB 2001 for relapsed/refractory multiple myeloma
News | May 06, 2025

Ichnos Glenmark Innovation receives USFDA fast track designation for ISB 2001 for relapsed/refractory multiple myeloma

IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma


GSK to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
News | November 01, 2024

GSK to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline

CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus


Lonza launches new cell culture media system TheraPRO
News | July 18, 2023

Lonza launches new cell culture media system TheraPRO

The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production


AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData
Drug Approval | September 13, 2022

AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData

Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.


RNAGene and PharmAbcine to develop novel mRNA therapeutics
Biotech | March 21, 2022

RNAGene and PharmAbcine to develop novel mRNA therapeutics

mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody


NuclixBio and PharmAbcine sign collaborative research agreement
Biotech | March 15, 2022

NuclixBio and PharmAbcine sign collaborative research agreement

Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies


SAB Biotherapeutics’ SAB-185 moves to Phase 3 trial for Covid-19 treatment
Biotech | September 26, 2021

SAB Biotherapeutics’ SAB-185 moves to Phase 3 trial for Covid-19 treatment

Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors


SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants
Drug Approval | August 12, 2021

SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants

SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial